Introduction
Over the last two decades, a new biochemical/physiological system, known as the endocannabinoid system (ECS), was discovered [1,2]. There is considerable evidence that ECS not only plays a significant role in appetite drive and associated behaviours, but also in endocrine and metabolic regulation and energy balance [3] . Indeed, cannabinoid receptors, especially cannabinoid 1 receptor (CB1R), participate in the physiological modulation of many central and peripheral functions [3] . An overactivity of ECS has been consistently reported in patients with abdominal obesity and diabetes, and it is tempting to attenuate ECS overactivity in order to reduce body weight and visceral adipose tissue and improve metabolic disturbances, especially type 2 diabetes and atherogenic dyslipidaemia [4, 5, 6 ,7-9].
The aims of the present review are to analyse the effects of overactivity of ECS and CB1R blockade on glucose metabolism in both animals and humans and to summarize the current knowledge on the use of CB1R inhibitors, especially rimonabant, in the management of overweight/obese patients with type 2 diabetes and other cardiometabolic risk factors associated with abdominal obesity and insulin resistance. The clinical safety profile of rimonabant, especially the psychological concern (anxiety and depression) [10, 11 ] , and the recommendations of its best use in the right patient to optimize both efficacy and safety, especially in type 2 diabetes [12, 13, 14 ], have been extensively reviewed recently and will not be discussed further in the present study.
Role of endocannabinoid system and cannabinoid 1 receptors in glucose metabolism
There is increasing evidence in humans for ECS overactivity during conditions of unbalanced energy homeostasis, that is, obesity (especially abdominal obesity) and diabetes, and for its causative role in these disorders [15 ,16] . Human adipocytes have been identified as an important source of endocannabinoids [anandamide (AEA) and 2-arachidonoyl glycerol (2-AG)] [17] . Higher levels of 2-AG were shown in the serum and visceral, but not in the subcutaneous fat of obese subjects [18] . Circulating 2-AG was significantly correlated with body fat, visceral fat mass and fasting plasma insulin concentrations but negatively correlated with glucose infusion rate during a glucose clamp [19] . In untreated asymptomatic men, plasma 2-AG levels correlated positively with BMI, waist girth, intraabdominal adiposity, fasting triglycerides and insulin levels, and negatively with HDL-C and adiponectin levels [20 ] . The ECS activation in obese visceral adipose tissue was accompanied by an elevated expression of the proinflammatory cytokine tumour necrosis factor-a (TNF-a), which is known to increase insulin resistance [21] . Following hyperinsulinaemia resulting from a euglycaemic hyperinsulinaemic clamp, the mRNA levels of fatty acid amide hydroxylase (FAAH), an enzyme that degrades endocannabinoids, increased two-fold in the subcutaneous abdominal adipose tissue from lean individuals but not from obese ones. The FAAH gene expression correlated positively with the fasting serum insulin concentration, whereas an inverse association with the whole-body glucose disposal was seen [22] . All together, these findings suggest that intra-abdominal fat accumulation is a critical correlate of peripheral ECS dysregulation, and that ECS may represent a primary target for the treatment of abdominal obesity and associated metabolic changes, including type 2 diabetes. It is worth noting, however, that no association was found in a recent study between either subcutaneous or omental adipose tissue CB1R gene mRNA levels and BMI, waist circumference, plasma levels of glucose and insulin or lipids [23 ] .
CB1Rs play the most important role in energy control and metabolic regulation. They are found not only in the brain but also in the gut [24] , liver [25] , skeletal muscle [26] and pancreas [18, 27] , all organs playing a key role in the regulation of glucose metabolism and the pathophysiology of type 2 diabetes (Fig. 1 ) [28 ] . ECS overactivity may deteriorate glucose metabolism by increasing hepatic glucose output, by either decreasing muscular glucose uptake or by impairing insulin secretion or both, all abnormalities that might be directly or indirectly influenced by CB1R blockade.
Development of cannabinoid 1 receptor inhibitors
ECS overactivity may result either from increased endocannabinoid synthesis, CBR overexpression or decreased endocannabinoid degradation or all, processes that may theoretically be the target of pharmacological approaches [29] . However, the most advanced strategy consists of CB1R blockade. The diarylpyrazole derivative, SR141716 (rimonabant), was the first selective CB1R antagonist reported, extensively investigated and commercialized [30] [31] [32] . Some evidence suggests that rather than acting as a pure (neutral) antagonist, rimonabant might function as an inverse agonist, that is, have an intrinsic activity opposite to that of agonists or inhibit constitutive CB1R activity [6 ,33] . In addition to rimonabant, several other CB1R inverse agonists (e.g. taranabant) or pure antagonists have been synthesized and many are under development but, at present, little is known about them [14 ,34] .
Cannabinoid 1 inhibitors in animal models
Cannabinoid 1 knockout (CB1À/À) mice are lean and resistant to diet-induced obesity, with no deterioration of insulin sensitivity [3, 35] . Similar to genetic inactivation of CB1Rs, pharmacological CB1R antagonism with rimonabant reduced food intake and body weight [36] . Pairfeeding experiments, however, revealed that the reduced food intake in rimonabant-treated mice was transient and not sufficient to reduce body weight in untreated obese mice [37] . These observations have contributed to the hypothesis that peripheral endocannabinoids and, therefore, CB1R antagonism in peripheral organs, modulate metabolic regulation, independent of food intake [3, 8] .
Treatment of obese mice with CB1R antagonists induced several metabolic events in the adipose tissue such as enhanced lipolysis through the stimulation of enzymes involved in B-oxidation and the tricarboxylic acid cycle, increased energy expenditure through futile cycle induction and an improvement in glucose uptake through increased expression of glucose transporter-4, a key player in glucose metabolism [38] . Several findings in rodents indicate that ECS participates locally in adipogenesis and fat accumulation, partially by accelerating the appearance and stimulating the activity of peroxisome proliferatoractivated receptors-gamma (PPAR-g) [18] . A role for the local endocannabinoids in the regulation of glucose metabolism by phosphatidylinositol 3-kinase and calciumdependent mechanisms was also shown in human adipocytes [39] .
The production of adiponectin, an antiatherogenic and antidiabetic adipocyte-derived protein [40] , was increased by CB1R antagonists in fa/fa rats [41] . In a high-fat diet dog model, rimonabant, in contrast to placebo, induced a rapid and dramatic increase in plasma adiponectin levels that occurred in the absence of changes in body weight or omental fat [42 ] . These results suggest that CB1R antagonism can raise and sustain plasma adiponectin levels during high-fat feeding, an effect that may account for the concomitant increase in insulin sensitivity [40] . However, one recent human study found no relation between adipose tissue CB1R gene expression and adiponectin mRNA, adipose tissue adiponectin secretion or circulating adiponectin [23 ] .
In the liver, endocannabinoids induce the expression of a cluster of genes that stimulate hepatic fat synthesis, including the lipogenic transcription factor, sterol regulatory element-binding protein (SREBP)-1c, and the key lipogenic enzymes acetyl coenzyme A carboxylase-1 and fatty acid (FA) synthase. As a result, CB1R activation significantly increased FA synthesis in normal mice, whereas the effect by CB1R agonist was not observed in CB1R knockout mice [36] . This demonstrates that endocannabinoids promote lipogenesis and steatosis through cannabinoid 1 receptors. More importantly, the marked increase in the basal rate of hepatic FA synthesis as well as the development of hepatic steatosis observed after the administration of high-fat diet were blunted by rimonabant and were absent in CB1À/À mice [22] . Chronic treatment with rimonabant also reduced obesity-associated hepatic steatosis and features of metabolic syndrome, especially dyslipidaemia, in obese Zucker fa/fa rats [43] . Thus, rimonabant may be considered as a novel therapeutic option for nonalcoholic steatohepatitis [44] . This is important as fatty liver has been shown to be strongly associated with insulin resistance, increased hepatic glucose production and impaired glucose tolerance in humans [45, 46] .
An important target organ of CB1R antagonists in Lep(ob)/ Lep(ob) obese mice is the skeletal muscle. Indeed, a significant increase in the glucose uptake by isolated soleus muscle and oxygen consumption was observed in rimonabant-treated obese mice [26] . Endocannabinoids were reported to suppress FA oxidation in the skeletal muscle by affecting the expression of energy metabolismregulating genes including AMP-activated protein kinases a1 and a2, pyruvate dehydrogenase kinase 4 and PPAR-g coactivator-1a [47] . It is not known, however, if the stimulatory effect on glucose uptake by rimonabant results from a direct effect of the drug on skeletal muscle CB1Rs or an indirect effect due to the increase in insulin-sensitizing adipokine adiponectin [40] . This deserves further studies as skeletal muscle is a key organ playing a major role in the insulin resistance characterizing type 2 diabetes [28 ] .
Recent studies extended the potential role of the ECS to the endocrine pancreas [18,27,48 ,49] . In rats, the administration of AEA and its stable analogue, arachidonyl-2 0 -chloroethylamide, resulted in glucose intolerance after a glucose load, which may be due to the reduction of glucose-dependent insulin secretion [50] . Whereas stimulation of CB1Rs in the rat leads to glucose intolerance, activation of CB2Rs improved glucose handling after a glucose load, and blockade of CB2Rs counteracted this effect [50, 51] . Further in-vivo studies will be necessary to establish the impact of CB1R antagonists on pancreatic B-cells, especially in patients with type 2 diabetes.
Cannabinoid 1 inhibitors in human clinical trials
The only large long-term published trials concern rimonabant, both in nondiabetic and diabetic overweight/obese patients. Trials with other cannabinoid 1 modulators are ongoing (e.g. taranabant) or will start in the near future.
Rimonabant in nondiabetic overweight/obese patients
The rimonabant in obesity (RIO) programme comprised three large placebo-controlled randomized clinical trials (RCTs) in overweight/obese nondiabetic patients: two 2-year RCTs (RIO-Europe and RIO-North America) [52, 53 ,54] and one 1-year RCT (RIO-Lipids) specifically devoted to patients with untreated dyslipidaemia [55] . These three RCTs led to remarkably consistent results (Table 1) . After 1 year of follow up, rimonabant (20 mg), when combined with diet and exercise, produced a significant weight loss (À4.7-5.4 kg) and waist circumference reduction (À3.6-4.7 cm) as compared with placebo. In addition, improvements in multiple cardiovascular and metabolic risk factors were noticed [52, 54] , which persisted after 2 years [53 ,54] . In RIO-Lipids, part of these metabolic improvements could be attributed to a significant increase in plasma adiponectin levels with rimonabant (20 mg) [55] . Whereas fasting glucose levels remained almost unaffected in nondiabetic individuals, fasting plasma insulin concentrations and homeostasis model assessment (HOMA) insulin-resistance index (HOMA-IR) were significantly decreased in patients receiving rimonabant (20 mg) compared with those receiving placebo (Table 1) . Almost half (between 45 and 57%) of the overall treatment effects in year 1 on HDL-cholesterol (C), triglycerides, fasting insulin and insulin resistance were due to a direct effect not attributable to weight loss [11 ] , in agreement with pharmacologic effects of rimonabant in peripheral tissues [3, 8, 15 ].
To determine whether rimonabant improves glucose tolerance in overweight/obese nondiabetic patients, data were pooled from the two studies involving oral glucose tolerance tests (OGTTs) at baseline and 1 year (RIO-Lipids and RIO-Europe) and 2 years (RIO-Europe) [56] . After 1 year, rimonabant (20 mg) produced significantly greater reductions than placebo in plasma glucose (À0.64 vs. À0.37 mmol/l, P < 0.01) and insulin (À15.2 vs. À1.8 mIU/ml, P < 0.001) levels at 120 min after OGTT. Rimonabant reduced both glucose and insulin area under the plasma concentration-time curve values vs. placebo (P < 0.001 for both). Furthermore, rimonabant improved the distribution of glucose tolerance status at 1 year in the pooled intent-to-treat population (P < 0.01), with an increased proportion of patients with normal glucose tolerance and a decreased proportion of patients with impaired glucose tolerance or diabetes. Favourable effects on glucose tolerance status persisted after 2 years in RIO-Europe despite a weight stabilization from year 1 to year 2 [56] . These results demonstrate that rimonabant (20 mg) can reduce the progression of glucose intolerance in overweight/obese patients.
Rimonabant in overweight/obese patients with type 2 diabetes
The RIO-Diabetes trial investigated the efficacy and safety of rimonabant in overweight/obese patients with type 2 diabetes [57] . Therefore, 1047 patients (BMI 27-40 kg/m 2 ) with an HbA1c of 6.5-10.0% already on metformin (two-thirds of the study population) or sulfonylurea (one-third) monotherapy were given a mild hypocaloric diet and randomized to placebo or rimonabant for 1 year. Weight loss in the intent-to-treat population was greater after 1 year with rimonabant (20 mg) than with placebo (À5.3 vs. À1.4 kg; P < 0.001). Rimonabant (20 mg) improved HbA1c (À0.6% vs. þ0.1% for placebo; P < 0.001) in patients with mean baseline HbA1c of 7.3%, whatever is the initial oral antidiabetic therapy. In patients with higher HbA1c levels (!8%) at baseline, reductions of 0.3 and 1.1% were observed in the placebo and rimonabant (20 mg) treatment groups, respectively (P ¼ 0.001). The HbA1c improvement with rimonabant 20 mg was approximately twice than that expected from the observed weight loss alone. Waist circumference, HDL-C, triglycerides, fasting glucose levels, HOMA-IR, systolic blood pressure, metabolic syndrome prevalence and C-reactive protein levels also improved significantly with rimonabant (20 mg) compared with placebo (Table 1) . Plasma liver enzyme levels, especially alanine transferase (ALT), also decreased with rimonabant in patients with type 2 diabetes, in agreement with a reduction in insulin resistance and liver steatosis [44, 45] .
Study Evaluating Rimonabant Efficacy in drug-Naive Diabetic patients (SERENADE) is a 6-month placebocontrolled trial in overweight/obese patients with recentonset diabetes treated with diet alone. HbA1c (primary endpoint) decreased by 0.8% in the group receiving rimonabant (20 mg) compared with 0.3% in the group receiving placebo (P ¼ 0.0002; mean baseline HbA1c 7.9%) [58] . In patients with higher HbA1c levels (!8.5%) at baseline, reductions of 0.7 and 1.9% were observed in the placebo and rimonabant groups, respectively (P < 0.001). Rimonabant also decreased HOMA-IR and significantly increased plasma adiponectin levels (Table 1) as in the nondiabetic population of RIO-Lipids [55] . Again, almost half of the metabolic improvement occurred beyond weight loss (57% for HbA1c reduction) [58] .
Several ongoing trials will confirm the effectiveness of rimonabant in the prevention or in the management of type 2 diabetes, in patients treated with diet, various oral agents or even insulin (ARPEGGIO trial) [14 ] .
Taranabant in overweight/obese subjects MK-0364 (taranabant) is an acyclic CB1R inverse agonist, which at a daily dose of 12 mg may help overweight and obese patients in losing weight [59 ] . Mechanism-of-action studies suggest that modulation of CB1Rs by taranabant leads to weight loss by reducing the food intake and increasing the energy expenditure and fat oxidation. In an effort to minimize adverse effects, daily doses of 4 mg and 6 mg of taranabant are currently investigated in ongoing large phase III clinical trials in overweight/obese patients with or without type 2 diabetes.
Conclusion
Evidence suggests that CB1R blockade is a novel therapeutic strategy that addresses the underlying mechanisms of abdominal obesity, insulin resistance and glucose dysregulation. CB1R blockade resulted in reduced weight gain and improvement of multiple metabolic variables in various animal models. Following the RIO programme, rimonabant, a specific CB1R antagonist, is now commercialized in numerous countries as an adjunct to diet and exercise for the treatment of obese patients (BMI !30 kg/m 2 ) or overweight patients (BMI >27 kg/m 2 ) with associated risk factor(s) such as type 2 diabetes or dyslipidaemia. Importantly enough, almost half of the observed improvements in several metabolic parameters were beyond that expected from weight loss, in agreement with direct peripheral metabolic effects of rimonabant. However, specific studies are urgently needed to carefully investigate the effects of rimonabant on glucose utilization by skeletal muscle, hepatic glucose production and insulin secretion in insulin-resistant patients with impaired glucose tolerance or type 2 diabetes. An extended clinical development programme is ongoing, especially in patients with type 2 diabetes. Further studies should confirm the long-term efficacy (cardiovascular protection) and safety (psychological adverse events) of rimonabant and other CB1R antagonists.
